{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:14:37Z","timestamp":1787764477028,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00417-025-06938-y","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:55:12Z","timestamp":1755590112000},"page":"3493-3507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Network meta-analysis of immunomodulatory therapies for Beh\u00e7et\u2019s disease-associated uveitis: comparative evaluation of safety and efficacy profiles"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-8264","authenticated-orcid":false,"given":"Luksanaporn","family":"Krungkraipetch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Krungkraipetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechathorn","family":"Krungkraipetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"12","key":"6938_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B et al (2018) Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford) 57(12):2200\u20132212","journal-title":"Rheumatology (Oxford)"},{"key":"6938_CR2","unstructured":"Riancho-Zarrabeitia L, Calvo-R\u00edo V, Blanco R, Mesquida M, Adan AM, Herreras JM et al (2015) Anti-TNF-\u03b1 therapy in refractory uveitis associated with Beh\u00e7et\u2019s disease: 1-year follow-up results of a multicenter study. Clin Exp Rheumatol.;33(6 Suppl 94)"},{"issue":"12","key":"6938_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J et al (2019) Comparative study of Infliximab versus adalimumab in refractory uveitis due to beh\u00e7et\u2019s disease: National multicenter study of 177 cases. Arthritis Rheumatol 71(12):2081\u20132089","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"6938_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","volume":"36","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Sota J, Lucherini OM, Tosi GM, Frediani B et al (2017) IL-6 Blockades in the management of non-infectious uveitis. Clin Rheumatol 36(7):1459\u20131469","journal-title":"Clin Rheumatol"},{"issue":"4","key":"6938_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T (2020) Effectiveness of Tocilizumab in behcet\u2019s disease: a systematic literature review. Semin Arthritis Rheum 50(4):797\u2013804","journal-title":"Semin Arthritis Rheum"},{"key":"6938_CR6","doi-asserted-by":"crossref","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ.;350","DOI":"10.1136\/bmj.g7647"},{"issue":"1","key":"6938_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41(1):61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"6938_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02830","volume":"10","author":"A Bettiol","year":"2019","unstructured":"Bettiol A, Hatemi G, Vannozzi L, Barilaro A, Prisco D, Emmi G (2019) Treating the different phenotypes of beh\u00e7et\u2019s syndrome. Front Immunol 10:2830","journal-title":"Front Immunol"},{"issue":"1","key":"6938_CR9","first-page":"41","volume":"62","author":"G Ciprandi","year":"2020","unstructured":"Ciprandi G, Murdaca G, Colombo BM, De Lucia F, Marseglia G (2020) TNF-alpha in allergic inflammation and in immune system homeostasis. Panminerva Med 62(1):41\u201348","journal-title":"Panminerva Med"},{"key":"6938_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G (2019) Efficacy of the anti-IL 17 secukinumab in refractory beh\u00e7et\u2019s syndrome: a preliminary study. J Autoimmun 97:108\u2013113","journal-title":"J Autoimmun"},{"issue":"2","key":"6938_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.intimp.2009.11.004","volume":"10","author":"G Ciprandi","year":"2010","unstructured":"Ciprandi G, Filaci G, Battaglia F, Fenoglio D (2010) Peripheral Th-17 cells in allergic rhinitis: new evidence. Int Immunopharmacol 10(2):226\u2013229","journal-title":"Int Immunopharmacol"},{"issue":"20","key":"6938_CR12","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D et al (2019) Trial of apremilast for oral ulcers in beh\u00e7et\u2019s syndrome. N Engl J Med 381(20):1918\u20131928","journal-title":"N Engl J Med"},{"issue":"3","key":"6938_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol 142(3):429\u2013434","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6938_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ajo.2008.09.011","volume":"147","author":"M Roesel","year":"2009","unstructured":"Roesel M, Tappeiner C, Heiligenhaus A, Heinz C (2009) Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis. Am J Ophthalmol 147(3):406\u2013412","journal-title":"Am J Ophthalmol"},{"key":"6938_CR15","doi-asserted-by":"publisher","first-page":"n171","DOI":"10.1136\/bmj.N71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n171. https:\/\/doi.org\/10.1136\/bmj.N71","journal-title":"BMJ"},{"key":"6938_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"6938_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj","DOI":"10.1136\/bmj"},{"key":"6938_CR18","unstructured":"Schwarzer G (2024) meta: General Package for Meta-Analysis [Internet]. Version 7.0\u20130. R Foundation for Statistical Computing; Jan Available from: https:\/\/github.com\/guido-s\/meta\/"},{"issue":"1","key":"6938_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M (2008) Safety and efficacy of Infliximab therapy in active behcet\u2019s uveitis: an open-label trial. Rheumatol Int 29(1):53\u201357","journal-title":"Rheumatol Int"},{"issue":"2","key":"6938_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09273940701299370","volume":"15","author":"RR Buggage","year":"2007","unstructured":"Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm 15(2):63\u201370","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"6938_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13(3):246\u2013252","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"6938_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71(4):563\u2013566","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6938_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10384-021-00872-2","volume":"65","author":"Y Ida","year":"2021","unstructured":"Ida Y, Takeuchi M, Ishihara M, Shibuya E, Yamane T, Hasumi Y et al (2021) An open-label, prospective, single-arm study of switching from Infliximab to cyclosporine for refractory uveitis in patients with Beh\u00e7et\u2019s disease in long-term remission. Jpn J Ophthalmol 65(6):843\u2013848","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"6938_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, G\u00fcnaydin I et al (2004) Differential efficacy of human recombinant interferon-\u03b12a on ocular and extraocular manifestations of beh\u00e7et disease: results of an open 4-center trial. Semin Arthritis Rheum 33(5):311\u2013319","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"6938_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","volume":"74","author":"S Lightman","year":"2015","unstructured":"Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Moots R et al (2015) Pegylated interferon-\u03b1-2b reduces corticosteroid requirement in patients with beh\u00e7et\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis 74(6):1138\u20131144","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6938_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single Infliximab infusion vs corticosteroids for acute panuveitis attacks in beh\u00e7et\u2019s disease: a comparative 4-week study. Rheumatology (Oxford) 50(3):593\u2013597","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"6938_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/1756-185X.13095","volume":"20","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F (2017) High-dose intravenous steroid pulse therapy in ocular involvement of Behcet\u2019s disease: a pilot double-blind controlled study. Int J Rheum Dis 20(9):1269\u20131276","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"6938_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/jca.20076","volume":"21","author":"K Namba","year":"2006","unstructured":"Namba K, Sonoda KH, Kitamei H, Shiratori K, Ariyama A, Iwabuchi K et al (2006) Granulocytapheresis in patients with refractory ocular behcet\u2019s disease. J Clin Apher 21(2):121\u2013128","journal-title":"J Clin Apher"},{"issue":"1","key":"6938_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T (2019) Safety and efficacy of Infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther 21(1):2","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"6938_CR30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/IAE.0000000000003095","volume":"41","author":"M Refaat","year":"2021","unstructured":"Refaat M, Abdullatif AM, Hamza MM, Macky TA, El-Agha MH, Ragab G et al (2021) Monthly intravitreal Infliximab in beh\u00e7et\u2019s disease active posterior uveitis: a long-term safety study. Retina 41(8):1739\u20131747","journal-title":"Retina"},{"key":"6938_CR31","doi-asserted-by":"crossref","unstructured":"Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K et al (2024) Infliximab versus Cyclophosphamide for Severe Beh\u00e7et\u2019s Syndrome. NEJM Evid 3(11)","DOI":"10.1056\/EVIDoa2300354"},{"issue":"8","key":"6938_CR32","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52(8):2478\u20132484","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6938_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","volume":"25","author":"I Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, \u00d6zyazgan Y et al (2017) Safety and efficacy of Gevokizumab in patients with beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm 25(1):62\u201370","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"6938_CR34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","volume":"26","author":"I Tugal-Tutkun","year":"2018","unstructured":"Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, G\u00fcl A (2018) Use of Gevokizumab in patients with beh\u00e7et\u2019s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm 26(7):1023\u20131033","journal-title":"Ocul Immunol Inflamm"},{"key":"6938_CR35","doi-asserted-by":"crossref","unstructured":"Zhong Z, Deng D, Gao Y, Bu Q, Dai L, Feng X et al (2024) Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Beh\u00e7et\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. Lancet Rheumatol 6(11)","DOI":"10.1016\/S2665-9913(24)00194-2"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06938-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06938-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06938-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:39:16Z","timestamp":1770647956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06938-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6938"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06938-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review involved data analysis from previously published studies and did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Considerations"}},{"value":"Since this study did not involve recruiting participants or collecting new data, obtaining informed consent was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}